Novartis (NOVN SW) Q1 2026 (USD): Core EPS 1.99 (exp. 2.11), Revenue 13.1bln (exp. 13.6bln), Adj. Op. Income 4.9bln (exp. 5.09bln), reaffirms 2026 guidance

• Net sales expected to grow low single-digit and core operating income expected to decline low single-digit

CEO:

• "With the momentum we are seeing across the business, we remain on track to deliver our full year guidance and look forward to multiple readouts in the second half that could raise our mid- to long-term growth outlook.”

By drug:

• Strong growth across key drivers led by Kisqali and Pluvicto, partially offset by declines in Cosentyx and Zolgensma. (Novartis)
• Kisqali 1.516bln (prev. +55% Y/Y).
• Pluvicto 642mln (prev. +70% Y/Y).
• Kesimpta 1.164bln (prev. +26% Y/Y).
• Leqvio 452mln (prev. +69% Y/Y).
• Scemblix 433mln (prev. +79% Y/Y).
• Fabhalta 169mln (prev. +103% Y/Y).
• Rhapsody 37mln.
• Cosentyx 1.566bln (prev. -2% Y/Y).
• Zolgensma 302mln (prev. -12% Y/Y).